Dupixent 200 mg/1.14mL (Dupilumab INJECTION, SOLUTION) 200 mg/1.14mL

Dupilumab, the active ingredient in Dupixent, binds to the IL-4Rα subunit, blocking the signaling of interleukins 4 and 13. This action reduces type 2 inflammatory responses, which are involved in conditions like atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.

The dosage of Dupixent is determined by a healthcare provider based on the patient's condition, age, and weight. It is typically administered as a subcutaneous injection, with the specific dosing regimen prescribed by the doctor.

The safety of Dupixent during pregnancy or breastfeeding has not been fully established. It is important to consult with a healthcare provider to discuss the potential risks and benefits before using Dupixent in these situations.

To order Dupixent from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then provide pricing, availability, shipping, and the necessary import paperwork.

Dupixent is a biologic therapy that targets specific inflammatory pathways, making it effective for moderate-to-severe atopic dermatitis. Compared to topical treatments, it offers a systemic approach that can be more effective for widespread or severe symptoms. However, the choice of treatment depends on individual patient needs and should be discussed with a healthcare provider.

Dupixent should be stored at room temperature and protected from light. It is important not to shake the syringe before use. Always follow the instructions provided by your healthcare provider for proper administration and storage.

Dupixent is administered as a subcutaneous injection. It can be injected into the thigh, abdomen (except within 5 cm of the navel), or upper arm if administered by another person. The injection site should be rotated with each use, and the medication should not be injected into damaged or irritated skin.

The most serious risks associated with Dupixent include allergic reactions, such as anaphylaxis, and infections. Patients should be monitored for signs of infection or allergic reactions and should seek immediate medical attention if severe symptoms occur.

Dupixent should not be used by individuals with a known hypersensitivity to dupilumab or any of its components. It should also be used with caution in patients with a history of parasitic infections or those who are immunocompromised. Always consult a healthcare provider before starting Dupixent.